The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for the treatment of adult ...

With the right technology and support, CRAs can continue their evolution into powerful agents of trial success that bridge ...

In today’s ACT Brief, we examine how AI is being integrated into administrative workflows at investigative sites, highlight the FDA’s approval of the first gene therapy for adolescents and adults with ...

The FDA has approved Novartis’ Itvisma (onasemnogene abeparvovec-brve) for the treatment of adolescents two years and older, teens, and adults living with spinal muscular atrophy (SMA) with a ...

Artificial intelligence (AI) seems to be everywhere, but what is its future in clinical research? Clinical research inherently involves humans. However, it also involves numerous administrative ...

In today’s ACT Brief, we examine how AI and functional service partners are reshaping global pharmacovigilance, look at new ...

AI-enabled automation is rapidly moving into routine pharmacovigilance operations, streamlining case intake and processing, reducing longstanding adoption barriers, and driving new efficiencies as ...

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...

AI-enabled automation is rapidly moving into routine pharmacovigilance operations, streamlining case intake and processing, reducing longstanding adoption barriers, and driving new efficiencies as ...

How pharma–hospital partnerships can overcome operational, financial, and organizational barriers to build high-performing clinical trial programs that expand access, accelerate accrual, and ...

Explore methods to evaluate recruitment performance across multiple platforms, including engagement tracking, conversion ...

How pharma–hospital partnerships can overcome operational, financial, and organizational barriers to build high-performing clinical trial programs that expand access, accelerate accrual, and ...